STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNOA
  4. [8-K] Sonoma Pharmaceuticals, Inc. Reports Material Event

Sonoma Pharmaceuticals (SNOA) signs Kenvue U.S. Microcyn manufacturing and supply deal

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Sonoma Pharmaceuticals, Inc. entered into a new Manufacturing and Supply Agreement with Kenvue Brands LLC covering the sale of Microcyn® technology-based products in the United States. The agreement is effective from October 24, 2025 through March 2027, with an option for up to two additional one-year extensions by mutual written agreement.

The company notes that this description is only a summary and refers readers to the full agreement filed as Exhibit 10.1. Sonoma also includes standard forward-looking statement language, emphasizing that actual results could differ due to various risks and uncertainties outlined in its SEC reports.

Positive

  • None.

Negative

  • None.

Insights

Sonoma secures a U.S. supply deal for Microcyn products with Kenvue on a multi-year basis.

The agreement between Sonoma Pharmaceuticals and Kenvue Brands LLC provides a defined framework to manufacture and supply Microcyn® technology-based products in the United States. It runs from October 24, 2025 through March 2027, with potential annual extensions.

While no volumes or financial terms are disclosed here, partnering with a large consumer-health player for Microcyn-branded products can be strategically important, potentially broadening market reach. The impact will depend on actual order levels, pricing, and how actively Kenvue promotes these products over the contract term.

The filing highlights standard forward-looking statement risks and points investors to Sonoma’s Form 10-K and other SEC reports for broader risk factors. Future disclosures, such as revenue contributions or milestone updates tied to this agreement, would clarify how material this relationship becomes for Sonoma’s overall business.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Agreement effective date October 24, 2025 Effective date of Manufacturing and Supply Agreement with Kenvue
Initial agreement term end March 2027 Scheduled end of initial contract term
Potential extension period Up to two additional one-year terms Extension options upon mutual written agreement
Manufacturing and Supply Agreement financial
"we entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC"
Microcyn® technology-based products technical
"for the sale of Microcyn® technology-based products in the United States"
forward-looking statements regulatory
"This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
false 0001367083 0001367083 2026-04-08 2026-04-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 8, 2026

 

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-33216   68-0423298
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

5445 Conestoga Court, Suite 150

Boulder, CO 80301

(Address of principal executive offices)

(Zip Code)

 

(800) 759-9305

(Registrant’s telephone number, including area code)

 

Not applicable.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock SNOA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On April 8, 2026, we entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn® technology-based products in the United States. The agreement is effective as of October 24, 2025 through March 2027, subject to up to two additional one-year terms upon mutual written agreement.

 

The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed herewith as Exhibit 10.1.

  

This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our Annual Report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit    
Number   Description

10.1 †*

  

Manufacturing and Supply Agreement, effective October 24, 2025, by and between Sonoma Pharmaceuticals, Inc. and Kenvue Brands LLC.

104   Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).

 ___________________

 

† Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.
* Some exhibits or schedules to the agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedule or exhibit to the SEC upon request.

 

 

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SONOMA PHARMACEUTICALS, INC.
   
   
Date: April 9, 2026 By:  /s/ Amy Trombly
 

Name:

Title:

 Amy Trombly
Chief Executive Officer

 

 

 

 

 

 

 

 

 

 3 

Source: View Original Filing on SEC EDGAR

FAQ

What new agreement did Sonoma Pharmaceuticals (SNOA) enter with Kenvue Brands LLC?

Sonoma Pharmaceuticals signed a Manufacturing and Supply Agreement with Kenvue Brands LLC to provide Microcyn® technology-based products in the United States. The contract defines how Sonoma will manufacture and supply these products for Kenvue’s U.S. market activities over a multi-year period.

When is the Sonoma Pharmaceuticals–Kenvue Manufacturing and Supply Agreement effective and how long does it last?

The agreement is effective as of October 24, 2025 and continues through March 2027. It can be extended for up to two additional one-year terms if both Sonoma Pharmaceuticals and Kenvue Brands LLC agree in writing to renew.

Which products are covered by Sonoma Pharmaceuticals’ agreement with Kenvue Brands LLC?

The agreement covers Microcyn® technology-based products sold in the United States. These products use Sonoma’s Microcyn technology platform, and the contract governs manufacturing and supply arrangements so Kenvue can distribute them in its U.S. channels during the term.

Where can investors find full details of Sonoma Pharmaceuticals’ agreement with Kenvue?

Investors can review the complete Manufacturing and Supply Agreement, filed as Exhibit 10.1 to the Form 8-K. The company notes that its brief description is qualified by this exhibit, which contains the detailed terms, conditions, and obligations for both parties.

Does Sonoma Pharmaceuticals’ filing about the Kenvue agreement include financial terms?

The filing does not disclose specific financial terms such as pricing or volume commitments. It focuses on the existence, effective dates, and duration of the Manufacturing and Supply Agreement and directs readers to the full contract exhibit for additional detail, subject to permitted redactions.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents